文献速递血栓与止血

静脉血栓栓塞症延长期抗凝治疗中大出血发生率和危险因素的种族差异

Racial disparities in the incidence and risk factors of major bleeding during extended anticoagulant therapy for venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2025-08-05

该研究分析两个前瞻性队列(223名黑人和4314名白人参与者),比较首次无诱因或弱诱因静脉血栓栓塞症(VTE)延长期抗凝治疗期间出血风险的种族差异。黑人参与者大出血风险较白人高1.9倍(HR 1.87,95%CI 1.04-3.36),颅内出血调整后HR为2.35(95%CI 1.23-4.48);在评估为低危者中大出血发生率黑人2.5/100人年 vs 白人1.1/100人年。

要点

  • 延长期抗凝期间黑人较白人发生大出血的风险高1.9倍(HR 1.87,95%CI 1.04-3.36)。
  • 颅内出血调整后HR为2.35(95%CI 1.23-4.48),致死性出血无种族差异。
  • 低危组大出血发生率黑人2.5/100人年 vs 白人1.1/100人年,数值上更高。

核心结论

  • 黑人接受延长期抗凝治疗者大出血风险高于白人,且该效应在评估为低出血风险者中似乎持续存在;需要可推广至种族化人群的抗凝相关出血风险评估模型。

研究设计与样本

  • 分析两个前瞻性队列,纳入首次无诱因或弱诱因VTE且初始治疗≥3个月后继续抗凝的患者,黑人223例、白人4314例;主要结局为经裁定的国际血栓与止血学会定义的大出血。

主要发现

  • 黑人参与者出血危险因素患病率更高,大出血风险较白人高1.9倍(HR 1.87;95%CI 1.04-3.36)。
  • 校正出血危险因素后大出血的种族差异减弱,但颅内出血的差异未减弱(校正HR 2.35;95%CI 1.23-4.48)。
  • 在肾脏功能、血红蛋白、年龄、抗血小板药物模型评估为低危者中,黑人较白人大出血发生率数值上更高(2.5 vs 1.1/100人年)。
  • 致死性出血和临床相关非大出血未见种族差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend extended anticoagulation after a first unprovoked venous thromboembolism (VTE) for individuals at low risk of bleeding. However, racial disparities in bleeding risks during extended treatment remain understudied. OBJECTIVES: To compare risks of anticoagulant-associated bleeding and performance of a risk assessment model by racial group during extended VTE treatment. METHODS: We analyzed 2 prospective cohorts of patients (223 Black participants and 4314 White participants) with a first unprovoked/weakly provoked VTE who continued anticoagulation after ≥3 months of initial treatment. Primary outcome was adjudicated International Society on Thrombosis and Haemostasis-defined major bleeding. Secondary outcomes included intracranial hemorrhage, fatal bleeding, and clinically relevant nonmajor bleeding. We determined incidence and hazard ratios (HRs) by race, then adjusted for bleeding risk factors that included the Creatinine, Hemoglobin, Age, antiPlatelet model. RESULTS: Black participants had higher prevalence of bleeding risk factors and a 1.9-fold higher risk of major bleeding (HR, 1.87; 95% CI, 1.04-3.36) compared with White participants. Adjustment attenuated racial difference for major bleeding but not intracranial hemorrhage (adjusted HR, 2.35; 95% CI, 1.23-4.48). Among those classified as low risk by Creatinine, Hemoglobin, Age, antiPlatelet model, Black participants had numerically higher major bleeding incidence than White participants (2.5 vs 1.1 per 100 person-years). We did not observe racial disparities in fatal bleeding or clinically relevant nonmajor bleeding. CONCLUSION: Black individuals on extended anticoagulation have higher risk of major bleeding compared with White individuals. This effect appears to persist in those classified as low risk for bleeding. Risk assessment models for anticoagulant-associated bleeding that are generalizable to racialized populations are needed.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Omar D, Kovacs MJ, Lazo-Langner A, et al. Racial disparities in the incidence and risk factors of major bleeding during extended anticoagulant therapy for venous thromboembolism. J Thromb Haemost. 2025. PMID: 40769433. doi:10.1016/j.jtha.2025.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。